![BrightPath Biotherapeutics Co., Ltd. logo](/logos/4594.T.webp)
BrightPath Biotherapeutics Co., Ltd.
TSE:4594.T
Overview | Financials
Company Name | BrightPath Biotherapeutics Co., Ltd. |
Symbol | 4594.T |
Currency | JPY |
Price | 53 |
Market Cap | 4,387,938,847 |
Dividend Yield | 0% |
52-week-range | 43 - 148 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Kenichi Nagai |
Website | https://www.brightpathbio.com |
An error occurred while fetching data.
About BrightPath Biotherapeutics Co., Ltd.
BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD